Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit

Matthew D. Hall, James M. Anderson, Annaliesa Anderson, David Baker, Jay Bradner, Kyle R. Brimacombe, Elizabeth A. Campbell, Kizzmekia S. Corbett, Kara Carter, Sara Cherry, Lillian Chiang, Tomas Cihlar, Emmie De Wit, Mark Denison, Matthew DIsney, Courtney V. Fletcher, Stephanie L. Ford-Scheimer, Matthias Götte, Abigail C. Grossman, Frederick G. HaydenDaria J. Hazuda, Charlotte A. Lanteri, Hilary Marston, Andrew D. Mesecar, Stephanie Moore, Jennifer O. Nwankwo, Jules O'Rear, George Painter, Kumar Singh Saikatendu, Celia A. Schiffer, Timothy P. Sheahan, Pei Yong Shi, Hugh D. Smyth, Michael J. Sofia, Marla Weetall, Sandra K. Weller, Richard Whitley, Anthony S. Fauci, Christopher P. Austin, Francis S. Collins, Anthony J. Conley, Mindy I. Davis

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

The NIH Virtual SARS-CoV-2 Antiviral Summit, held on 6 November 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for coronavirus disease 2019 (COVID-19), including combinations of antivirals. Scientific experts from the public and private sectors convened virtually during a live videocast to discuss severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) targets for drug discovery as well as the preclinical tools needed to develop and evaluate effective small-molecule antivirals. The goals of the Summit were to review the current state of the science, identify unmet research needs, share insights and lessons learned from treating other infectious diseases, identify opportunities for public-private partnerships, and assist the research community in designing and developing antiviral therapeutics. This report includes an overview of therapeutic approaches, individual panel summaries, and a summary of the discussions and perspectives on the challenges ahead for antiviral development.

Original languageEnglish (US)
Pages (from-to)S1-S21
JournalJournal of Infectious Diseases
Volume224
DOIs
StatePublished - Jul 15 2021

Keywords

  • SARS-CoV-2
  • antiviral therapeutics
  • emerging modalities
  • preclinical
  • proteases
  • viral replication machinery

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit'. Together they form a unique fingerprint.

Cite this